

EXPRESS MAIL CERTIFICATE OF MAILING (37 CFR 1.10)Express Mail No. **EL474178307US**Docket No.
56029/2669Applicant(s):
Johnson et al.**APR 29 2002**
POSTAL OFFICESerial No.
09/476,290Filing Date
December 30, 1999Examiner
Michael D. PakGroup Art
1646Title:
NEURTURIN AND RELATED GROWTH FACTORSTO THE COMMISSIONER OF PATENTS AND TRADEMARKS

Transmitted herewith is:

1. Amendment and Response; and
2. Return Postcard.

RECEIVED
MAY 03 2002
TECH CENTER 1600/2900
Signature

Dated: 4/29/02

Daniel S. Kasten, Reg. No. 45,363
Thompson Coburn LLP
One US Bank Plaza, Suite 3500
St. Louis, Missouri 63101-9928
314-552-6305
314-552-7305 FAX

Customer No. 021888

I certify that the document is being deposited on
April 29, 2002 with the U.S. Postal Service as
Express Mail under 37 C.F.R. 1.10 and is addressed to the
Assistant Commissioner for Patents, Washington, D.C. 20231.

Express Mail No. EL474178307US



Signature of Person Mailing Correspondence

Daniel S. Kasten

Typed or Printed Name of Person Mailing Correspondence

P16B/REV01



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 03 2002

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

TECH CENTER 1600/2900

I hereby certify that this correspondence and documents referred to as enclosed therein are being deposited with the United States Postal Service on this 29th day of April, 2002 in an envelope as "Express Mail Post Office to Addressee", Mailing Label Number EL474178307US addressed to: BOX NON FEE AMENDMENT, Assistant Commissioner for Patents, Washington, D.C. 20231

Daniel S. Kasten

Application of:	Johnson et al.	Group No.:	1646
Serial No.:	09/476,290	Atty. Docket No.:	56029-2669
Filed:	12/30/1999		
For:	Neurturin and related growth factors	Examiner:	Pak, Michael D.

Box Non Fee Amendment
Commissioner of Patents and Trademarks
Washington, DC 20231

AMENDMENT AND RESPONSE

HONORABLE SIR:

Responsive to the official communication of March 27, 2002, Applicant submits the following Remarks.

It is not believed that extensions of time are required beyond those, which may otherwise be provided for in documents accompanying this Amendment. However, in the event that additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned for under 37 C.F.R. § 1.136(a), and any fees required therefore are hereby authorized to be charged to our Deposit Account 20-0823.

REMARKS

In response to the Examiner's request, dated March 27, 2002, for a brief explanation of all of the SEQ ID Nos in the application, applicants submit the following summaries. As per the telephone conversation between myself and Examiner Pak of earlier this month regarding this request, Applicants are submitting at this time summaries of only the sequences that are recited

Serial No. 09/476,290

in the currently pending claims. The summaries submitted herein are intended only to facilitate examination, and are in no way intended to substitute for the more extensive discussion supplied in the specification. These descriptions are not to be construed as limiting in any way the description provided in the specification. Applicants assert that the specification is self-explanatory, and that the sequences in question are adequately described therein. Again, these summaries are submitted in response to the Examiner's request solely for the purpose of facilitating examination.

SEQ ID NO:1 is a polypeptide sequence of human Neurturin.

SEQ ID NO:2 is a polypeptide sequence of mouse Neurturin.

SEQ ID NO:7 is a polypeptide sequence of human pre-pro Neurturin.

SEQ ID NO:8 is a polypeptide sequence of mouse pre-pro Neurturin.

SEQ ID NO:33, 34, 35, 36, 37, 38, 39, 40 or 41 represent a region of a Neurturin polypeptide that are conserved among species.

Applicants believe that this response is complete, and respectfully request examination on the merits.

Respectfully submitted,



Daniel S. Kasten, Reg. #45363
Thompson Coburn LLP
One US Bank Plaza
St. Louis, Missouri 63101
Telephone: 314-552-6305
Fax: 314-552-7305